Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of the Route and Schedule of Immunization on the Serological and Virological Response of Chronic Hepatitis B Patients Treated with HeberNasvac.
Freyre FM, Aguiar JA, Cinza Z, Figueroa N, Diaz PA, Muzio VL, Lemos G, Freyre G, Coizeau E, Rodríguez C, Pentón E, Campos M, Santos IL, Mahtab MA, Akbar SMF, Guillen GE, Aguilar JC. Freyre FM, et al. Among authors: guillen ge. Euroasian J Hepatogastroenterol. 2023 Jul-Dec;13(2):73-78. doi: 10.5005/jp-journals-10018-1402. Euroasian J Hepatogastroenterol. 2023. PMID: 38222949 Free PMC article.
Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow-up results of phase IIa clinical study.
Yoshida O, Akbar SMF, Imai Y, Sanada T, Tsukiyama-Kohara K, Miyazaki T, Kamishita T, Miyake T, Tokumoto Y, Hikita H, Tsuge M, Shimizu M, Al Mahtab M, Aguilar JC, Guillen G, Kohara M, Hiasa Y. Yoshida O, et al. Hepatol Res. 2023 Mar;53(3):196-207. doi: 10.1111/hepr.13851. Epub 2022 Nov 18. Hepatol Res. 2023. PMID: 36399406
HeberNasvac, a Therapeutic Vaccine for Chronic Hepatitis B, Stimulates Local and Systemic Markers of Innate Immunity: Potential Use in SARS-CoV-2 Postexposure Prophylaxis.
Fleites YA, Aguiar J, Cinza Z, Bequet M, Marrero E, Vizcaíno M, Esquivel I, Diaz M, Sin-Mayor A, Garcia M, Martinez SM, Beato A, Galarraga AG, Mendoza-Mari Y, Valdés I, García G, Lemos G, González I, Canaán-Haden C, Figueroa N, Oquendo R, Akbar SM, Mahtab MA, Uddin MH, Guillén GE, Muzio VL, Pentón E, Aguilar JC. Fleites YA, et al. Among authors: guillen ge. Euroasian J Hepatogastroenterol. 2021 Jul-Dec;11(2):59-70. doi: 10.5005/jp-journals-10018-1344. Euroasian J Hepatogastroenterol. 2021. PMID: 34786358 Free PMC article.
Gradual reduction of testosterone using a gonadotropin-releasing hormone vaccination delays castration resistance in a prostate cancer model.
Barranco JA, Millar RP, Fuentes F, Bover E, Pimentel E, Basulto R, Calzada L, Morán R, Rodríguez A, Garay H, Reyes O, Castro MD, Bringas R, Arteaga N, Toudurí H, Rabassa M, Fernández Y, Serradelo A, Hernández E, Guillén GE. Barranco JA, et al. Among authors: guillen ge. Oncol Lett. 2016 Aug;12(2):963-970. doi: 10.3892/ol.2016.4679. Epub 2016 Jun 7. Oncol Lett. 2016. PMID: 27446378 Free PMC article.
Immunotherapy of prostate cancer in a murine model using a novel GnRH based vaccine candidate.
Junco JA, Peschke P, Zuna I, Ehemann V, Fuentes F, Bover E, Pimentel E, Basulto R, Reyes O, Calzada L, Castro MD, Arteaga N, López Y, Garay H, Hernández H, Bringas R, Guillén GE. Junco JA, et al. Among authors: guillen ge. Vaccine. 2007 Dec 5;25(50):8460-8. doi: 10.1016/j.vaccine.2007.09.033. Epub 2007 Oct 4. Vaccine. 2007. PMID: 18022737
14 results